Hemispherx Ampligen Advisory Cmte. Will Be Early Test Of FDA Focus On Chronic Fatigue Syndrome
This article was originally published in The Pink Sheet Daily
Executive Summary
Ampligen has a shot at becoming the first drug approved for chronic fatigue syndrome, with an advisory panel tentatively slated for Dec. 20. FDA recently unveiled plans to encourage drug development for this condition.
You may also be interested in...
Chronic Fatigue Syndrome Drug Development Efforts Get A Boost From FDA
Agency is undertaking a series of activities with patients, advocacy groups and other stakeholders aimed at spurring development of new treatments. Hemispherx is hoping its investigational drug Ampligen, currently under FDA review, will become an early beneficiary of new statutory provisions on expedited approval.
Ampligen Will Be Early Test Of FDA Consolidation Of Chronic Fatigue Drug Reviews
FDA’s decision to consolidate oversight for chronic fatigue syndrome treatments in the Division of Pulmonary, Allergy and Rheumatology Products will face an early test with Hemispherx Biopharma Inc.’s expected submission of an amended NDA for its investigational agent Ampligen in the third quarter.
Chronic Fatigue Drug Moving Slowly: Hemispherx's Ampligen Gets "Complete Response"
FDA wants more of everything, from clinical trials to resolution of manufacturing issues.